Bellerophon Therapeutics Performance
| BLPHDelisted Stock | USD 0.71 0.01 1.43% |
The firm shows a Beta (market volatility) of -1.26, which signifies a somewhat significant risk relative to the market. As returns on the market increase, returns on owning Bellerophon Therapeutics are expected to decrease by larger amounts. On the other hand, during market turmoil, Bellerophon Therapeutics is expected to outperform it. Bellerophon Therapeutics right now shows a risk of 0.0%. Please confirm Bellerophon Therapeutics maximum drawdown and the relationship between the kurtosis and period momentum indicator , to decide if Bellerophon Therapeutics will be following its price patterns.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Bellerophon Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite fairly strong basic indicators, Bellerophon Therapeutics is not utilizing all of its potentials. The current stock price confusion, may contribute to short-horizon losses for the traders. ...more
| Begin Period Cash Flow | 25.1 M |
Bellerophon |
Bellerophon Therapeutics Relative Risk vs. Return Landscape
If you would invest 71.00 in Bellerophon Therapeutics on September 3, 2024 and sell it today you would earn a total of 0.00 from holding Bellerophon Therapeutics or generate 0.0% return on investment over 90 days. Bellerophon Therapeutics is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Bellerophon, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Bellerophon Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bellerophon Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Bellerophon Therapeutics, and traders can use it to determine the average amount a Bellerophon Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| BLPH |
Based on monthly moving average Bellerophon Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bellerophon Therapeutics by adding Bellerophon Therapeutics to a well-diversified portfolio.
Bellerophon Therapeutics Fundamentals Growth
Bellerophon Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Bellerophon Therapeutics, and Bellerophon Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bellerophon Pink Sheet performance.
| Return On Equity | -1.39 | ||||
| Return On Asset | -0.6 | ||||
| Profit Margin | (2.20) % | ||||
| Operating Margin | (2.48) % | ||||
| Current Valuation | (9.32 M) | ||||
| Shares Outstanding | 12.23 M | ||||
| Price To Earning | 5.33 X | ||||
| Price To Book | 1.05 X | ||||
| EBITDA | (22.39 M) | ||||
| Cash And Equivalents | 16.33 M | ||||
| Cash Per Share | 1.71 X | ||||
| Total Debt | 203 K | ||||
| Debt To Equity | 0.05 % | ||||
| Book Value Per Share | 0.46 X | ||||
| Cash Flow From Operations | (17.77 M) | ||||
| Earnings Per Share | (0.34) X | ||||
| Total Asset | 7.93 M | ||||
| Retained Earnings | (252.08 M) | ||||
| Current Asset | 29.45 M | ||||
| Current Liabilities | 8.07 M | ||||
About Bellerophon Therapeutics Performance
By evaluating Bellerophon Therapeutics' fundamental ratios, stakeholders can gain valuable insights into Bellerophon Therapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Bellerophon Therapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Bellerophon Therapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey. Bellerophon Ther operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 20 people.Things to note about Bellerophon Therapeutics performance evaluation
Checking the ongoing alerts about Bellerophon Therapeutics for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Bellerophon Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bellerophon Therapeutics is not yet fully synchronised with the market data | |
| Bellerophon Therapeutics has some characteristics of a very speculative penny stock | |
| Bellerophon Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| Net Loss for the year was (19.83 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Bellerophon Therapeutics currently holds about 16.33 M in cash with (17.77 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.71, which can makes it an attractive takeover target, given it will continue generating positive cash flow. |
- Analyzing Bellerophon Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bellerophon Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Bellerophon Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bellerophon Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bellerophon Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bellerophon Therapeutics' pink sheet. These opinions can provide insight into Bellerophon Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey. You can also try the Portfolio Analyzer module to portfolio analysis module that provides access to portfolio diagnostics and optimization engine.
Other Consideration for investing in Bellerophon Pink Sheet
If you are still planning to invest in Bellerophon Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Bellerophon Therapeutics' history and understand the potential risks before investing.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Portfolio Analyzer Portfolio analysis module that provides access to portfolio diagnostics and optimization engine | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |